Crystal Form D of Pyrazine-2(1H)-ketone for FGFR Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting fibroblast growth factor receptors (FGFR) lack specificity and stability, particularly in inhibiting FGFR2 and FGFR3 while minimizing effects on FGFR1 and FGFR4, which is crucial for treating associated diseases effectively.
Innovation Solution
A crystal form D of a pyrazine-2(1H)-ketone compound with specific X-ray powder diffraction peaks and thermal analysis profiles, exhibiting good stability and selective inhibitory activity against FGFR2 and FGFR3, is developed, along with a method for its formulation and synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FGFR therapies are used, then FGFR inhibition is achieved, but selectivity between FGFR2/3 and FGFR1/4 is insufficient
Solution Approach 1:
The patent modifies the chemical structure parameters of the pyrazine-2(1H)-ketone compound to achieve differential binding affinity. Specifically, the compound structure (formula I) with particular substituent groups at defined positions creates selective interaction with FGFR2 and FGFR3 binding pockets while minimizing interaction with FGFR1 and FGFR4, thereby resolving the selectivity contradiction through precise molecular parameter optimization
2Stability of the object's composition
If crystal form D is used, then stability and formulation ease are improved, but additional characterization and validation steps are required
Solution Approach 1:
The patent identifies and characterizes specific local properties of crystal form D through distinctive XRPD peaks at defined 2θ angles. By establishing these specific diffraction patterns as identification markers, the patent enables targeted quality control that focuses on critical stability-related characteristics rather than comprehensive analysis, thereby managing complexity while ensuring stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal form D demonstrates high selectivity and inhibitory activity against FGFR2 and FGFR3, with good pharmacokinetic profiles, enhancing therapeutic efficacy while maintaining stability for drug formulation.
Implementation Method 1
The X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 9.42 ± 0.20°, 26.28 ± 0.20°, and 27.72 ± 0.20°
Implementation Method 2
The X-ray powder diffraction pattern of the crystal form D of compound of formula (II) has characteristic diffraction peaks
Implementation Method 3
the differential scanning calorimetry curve of the crystal form D of the compound of formula (II) has an endothermic peak with an onset at 179.1 °C ± 2.0 °C
Implementation Method 4
the thermogravimetric analysis curve of the crystal form D of the compound of formula (II) shows a weight loss of 7.11% at 190.0 °C ± 3.0 °C
Data Source
Figure 1~2
Figure 3
AI summary
Disclosed are a crystal form of pyrazine-2(1H)-ketone compound and a preparation method therefor. Specifically disclosed is a method for preparing a compound of formula (II) and a crystal form thereof.